All the Active Ingredient Drugs
GIP and GLP-1 receptor agonist. Tirzepatide 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. Pre-filled pen with 4 doses. Sol. for SC inj. 2.5/5/7.5/10/12.5/15 mg /dose
Starting dose 2.5 mg once/week. After 4 weeks, incr. to 5 mg once/week. If needed, can be incr. in 2.5 mg after a min. of 4 weeks on curr. dose.
Recomm. maint. doses are 5 mg, 10 mg and 15 mg.
Max. dose is 15 mg once/week.
Type 2 diabetes mellitus: for adlts with insuffic. contr. type 2 diabetes mellitus as an adjunct to diet and exercise
• as monother. when metformin is inappropr. due to intol. or contraindic.
• in addit. to other med. prods. for the tmt. of diabetes
Weight management: as an adjunct to a reduc.-calor. diet and incr. phys. act. for weight management, incl. weight loss and weight maint., in adlts with an initial Body Mass Index (BMI) of
• ≥ 30 kg/m2 (obesity) or
• ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the pres. of at least one weight-rel. comorbid condit. (e.g., hypertension, dyslipidaemia, obstruct. sleep apnoea, cardiovasc. dis., prediabetes, or type 2 diabetes mellitus).
C/I: Hypersens.
